Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Innovative Industrial Properties Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Innovative Industrial Properties Inc trades at $62.64 (market cap $1.79B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.5× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 12.3% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | IIPR | |
|---|---|---|
Market Cap | $4.49B | $1.79B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $63.40 |
52-Week Low | $20.06 | $44.58 |
Enterprise Value | $3.69B | $2.18B |
Dividend Yield | — | 12.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
IIPR trades at $61.81, down 2.51% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $1.88 versus $1.07 expected, though revenue has declined from $310M in 2023 to $266M in 2025. Recent news highlights progress on cannabis rescheduling as a potential tailwind and the declaration of a $1.90 dividend for Q2 2026.
The outlook is mixed; a high dividend yield and low P/E of 15.78 offer value, but declining revenue and negative net cash flow pose risks. Analyst sentiment is cautious with a majority Hold rating. Upside depends on stabilizing tenant operations and regulatory progress, while downside risks include further revenue pressure and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
